Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
Cadrenal Therapeutics (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, announced its participation in the Lytham Partners Fall 2024 Investor Conference. The virtual event will take place on Tuesday, October 1, 2024.
Key points:
- Cadrenal will deliver a webcast presentation at 2:00 pm ET
- The presentation will be accessible via the conference home page or a direct link
- Company management will participate in virtual one-on-one meetings with investors
- Investors can arrange meetings through Lytham Partners or by registering for the event
Tecarfarin is described as a new vitamin K antagonist designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
Cadrenal Therapeutics (Nasdaq: CVKD), un'azienda biofarmaceutica in fase avanzata che sta sviluppando tecarfarin, ha annunciato la sua partecipazione alla Conferenza per Investitori Lytham Partners Autunno 2024. L'evento virtuale si terrà martedì 1 ottobre 2024.
Punti chiave:
- Cadrenal condurrà una presentazione in webcast alle 14:00 ET
- La presentazione sarà accessibile tramite la home page della conferenza o un link diretto
- La direzione dell'azienda parteciperà a incontri virtuali uno a uno con gli investitori
- Gli investitori possono organizzare incontri tramite Lytham Partners o registrandosi per l'evento
Tecarfarin è descritto come un nuovo antagonista della vitamina K progettato per essere un anticoagulante cronico superiore e più sicuro per i pazienti dipendenti da warfarin con dispositivi cardiaci impiantati o condizioni cardiovascolari rare.
Cadrenal Therapeutics (Nasdaq: CVKD), una empresa biofarmacéutica en etapa avanzada que desarrolla tecarfarin, anunció su participación en la Conferencia de Inversores Lytham Partners Otoño 2024. El evento virtual se llevará a cabo el martes 1 de octubre de 2024.
Puntos clave:
- Cadrenal realizará una presentación en webcast a las 2:00 p.m. ET
- La presentación será accesible a través de la página principal de la conferencia o un enlace directo
- La administración de la empresa participará en reuniones virtuales uno a uno con inversores
- Los inversores pueden organizar reuniones a través de Lytham Partners o registrándose para el evento
Tecarfarin se describe como un nuevo antagonista de la vitamina K diseñado para ser un anticoagulante crónico superior y más seguro para pacientes dependientes de warfarina con dispositivos cardíacos implantados o condiciones cardiovasculares raras.
Cadrenal Therapeutics (Nasdaq: CVKD)은 테카르파린을 개발 중인 후기 단계의 생물 제약 회사로, 리탐 파트너스 2024 가을 투자자 회의에 참가한다고 발표했습니다. 이 가상 이벤트는 2024년 10월 1일 화요일에 열릴 예정입니다.
주요 사항:
- Cadrenal은 오후 2:00 ET에 웹캐스트 발표를 진행합니다.
- 발표는 회의 홈페이지나 직접 링크를 통해 접근할 수 있습니다.
- 회사의 경영진은 투자자들과 가상 일대일 회의에 참석할 것입니다.
- 투자자들은 리탐 파트너스를 통해 회의를 조정하거나 이벤트에 등록하여 회의를 예약할 수 있습니다.
테카르파린은 심장 기기가 이식된 환자나 드문 심혈관 질환을 가진 환자에게 더 우수하고 안전한 만성 항응고제로 설계된 새로운 비타민 K 길항제로 설명됩니다.
Cadrenal Therapeutics (Nasdaq: CVKD), une entreprise biopharmaceutique en phase avancée développant tecarfarin, a annoncé sa participation à la Conférence des Investisseurs Lytham Partners Automne 2024. L'événement virtuel aura lieu le mardi 1er octobre 2024.
Points clés :
- Cadrenal fera une présentation en webcast à 14h00 ET
- La présentation sera accessible via la page d'accueil de la conférence ou un lien direct
- La direction de l'entreprise participera à des réunions virtuelles individuelles avec des investisseurs
- Les investisseurs peuvent organiser des réunions via Lytham Partners ou en s'inscrivant à l'événement
Tecarfarin est décrit comme un nouvel antagoniste de la vitamine K conçu pour être un anticoagulant chronique supérieur et plus sûr pour les patients dépendants de la warfarine ayant des dispositifs cardiaques implantés ou des conditions cardiovasculaires rares.
Cadrenal Therapeutics (Nasdaq: CVKD), ein Biopharma-Unternehmen in der späten Entwicklungsphase, das tecarfarin entwickelt, hat seine Teilnahme an der Lytham Partners Herbst 2024 Investorenkonferenz angekündigt. Die virtuelle Veranstaltung findet am Dienstag, den 1. Oktober 2024 statt.
Wichtige Punkte:
- Cadrenal wird um 14:00 Uhr ET eine Webcast-Präsentation halten
- Die Präsentation ist über die Startseite der Konferenz oder einen direkten Link zugänglich
- Das Management des Unternehmens wird an virtuellen Einzelgesprächen mit Investoren teilnehmen
- Investoren können über Lytham Partners Meetings vereinbaren oder sich für die Veranstaltung registrieren
Tecarfarin wird als neuer Vitamin-K-Antagonist beschrieben, der als überlegener und sicherer chronischer Antikoagulans für Patienten, die auf Warfarin angewiesen sind und implantierbare Herzgeräte oder seltene Herz-Kreislauf-Erkrankungen haben, konzipiert wurde.
- None.
- None.
Company Webcast
Cadrenal's webcast presentation will begin at 2:00 pm ET on Tuesday, October 1. Access will be available via the conference home page at https://lythampartners.com/fall2024/ or directly at https://app.webinar.net/5daO3nGQlzP. The webcast will also be available for replay following the event.
One-on-one Meetings
Cadrenal management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg/.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is a late-stage biopharmaceutical company boldly challenging the status quo by innovating a new anticoagulant to elevate care for underserved patients. The company is developing the vitamin K antagonist (VKA) tecarfarin, designed to be a superior and safer anticoagulant for individuals with implanted cardiac devices or rare cardiovascular conditions. Cadrenal strives to improve outcomes and reduce major events for these patients, who lack chronic anticoagulation options besides warfarin, well-known for its prevalent side effects and cumbersome dosing. With its innovation, the company aims to unburden these patients and their healthcare providers from warfarin's many challenges.
Cadrenal's late-stage drug candidate tecarfarin is a new VKA anticoagulant that is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin. Tecarfarin received an orphan drug designation for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal trials along with clinical and commercial partnership opportunities. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-lytham-partners-fall-2024-investor-conference-302255020.html
SOURCE Cadrenal Therapeutics, Inc.
FAQ
When is Cadrenal Therapeutics (CVKD) participating in the Lytham Partners Fall 2024 Investor Conference?
What time is Cadrenal Therapeutics' (CVKD) webcast presentation at the Lytham Partners conference?
How can investors access Cadrenal Therapeutics' (CVKD) webcast presentation at the Lytham Partners conference?
What product is Cadrenal Therapeutics (CVKD) developing according to the press release?
How can investors arrange one-on-one meetings with Cadrenal Therapeutics (CVKD) management at the Lytham Partners conference?
